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Background: This study aims to evaluate the influence of changes in the teaching contents on medication-related 
osteonecrosis of the jaw may have on the knowledge and the capacity for practical case resolution about this pa-
thology.
Material and Methods: A cross-sectional descriptive study was conducted through a survey divided into four sec-
tions: degree of means of knowledge acquisition, habitual practice and ability to solve clinical cases. The total 
number of respondents (n = 225) was divided into two groups: Group A (Year 2015-2016) and Group B (Year 2016-
2017). The students in Group B received more teaching content on the subject than group A.
Results: A total of 175 survey responses were collected. The internet was the preferred tool for continuing educa-
tion in both groups. The best known bisphosphonates (BPs) were Alendronate (Fosamax®: 56.9% Group A, 67.5% 
Group B) and Zoledronic Acid (Zometa®: 56.9% Group A, 51.8% Group B). A low percentage of students (37.9% 
Group A, 43.4% Group B) acknowledged the existence of other drugs that could also cause osteonecrosis of the 
jaws. Regarding the correct resolution of practical cases, the respondents of Group B reached a significantly higher 
score (5.67) than the score observed in Group A (4.04). 
Conclusions: Training on medication-related osteonecrosis among dental students is susceptible to improvement. 
Introducing minor changes in the teachings allows this goal to be successfully achieved. 
Key words: Osteonecrosis of the jaw (ONJ), bisphosphonate-related osteonecrosis of the jaws (BRONJ), medica-
tion-related osteonecrosis of the jaw (MRONJ), dental education.
doi:10.4317/jced.54129
http://dx.doi.org/10.4317/jced.54129
Article Number: 54129               http://www.medicinaoral.com/odo/indice.htm







Escobedo MF, García-Consuegra L, Gay S, Álvarez L, Olay S, Ascani 
G, Junquera L. Influence of the teaching program on the learning in 
knowledge and practice of osteonecrosis of the jaws produced by anti-
reasorptives in dental students of the Principality of Asturias (Spain). J 
Clin Exp Dent. 2017;9(12):e1402-7.
http://www.medicinaoral.com/odo/volumenes/v9i12/jcedv9i12p1402.pdf
J Clin Exp Dent. 2017;9(12):e1402-7.                                                                                                                                         Osteonecrosis of the jaws produced by antireasorptives
e1403
Introduction
In September 2003, the first case series (36 patients) 
was published in the United States (1), which showed 
a relation between the use of aminobisphosphona-
tes and the occurrence of bone exposure in the jaws. 
Since then, different terms have been coined (2): bis-
phosphonate-associated osteonecrosis of the jaws 
(BAONJ), bisphosphonate-related osteonecrosis of the 
jaws (BRONJ), bisphosphonate-induced osteonecrosis 
of the jaws (BIONJ), bisphosphonate-related osteone-
crosis (BRON), or simply bisphosphonate osteonecro-
sis (BON). In the last thirteen years, a great number of 
works have been published in international literature 
about BRONJ in different countries around the world. 
In Spain, the first case series was published in 2005 by 
Bagán et al. (3) on 10 patients in the Valencian Commu-
nity. All were advanced stage cancer patients who had 
received different chemotherapeutic agents along with 
zoledronic acid and / or pamidronate. Subsequently, nu-
merous references of BRONJ appeared in the literature 
on patients with osteoporosis who had been taking ami-
nobisphosphonate orally, although the risk of BRONJ is 
lower than in patients who are intravenously treated with 
zoledronic acid (4,5). In 2007, the HORIZONT PTF (6) 
clinical trial recognized the efficacy of annual intrave-
nous doses of zoledronic acid (5 mgr) for the treatment 
of patients with osteoporosis. Although BRONJ is not 
reported as having adverse effects on the treatment in 
this study, few papers have recently been published re-
garding this complication (7,8).
In 2014, the American Association of Oral and Maxillo-
facial Surgeons (AAOMS) (9) confirmed the relation of 
other drugs (Denosumad, Sunitinib, Sorafenib, Bevaci-
zumab, Sirolimus, and others) dissimilar to BPs with the 
occurrence of chemical osteonecrosis of the jaws. The-
refore, the concept of BRONJ has now been changed by 
the concept of medication-related osteonecrosis of the 
jaw (MRONJ).
The frequency of MRONJ is anecdotal for different 
specialists who prescribe these drugs (urologists, gy-
necologists, traumatologists, rheumatologists, primary 
care physicians, oncologists and those responsible for 
bone and mineral metabolism units). Even some general 
dentists question the true existence of MRONJs, even 
though they are one of the main components in their pre-
vention.
In 2015, Alhussain et al. (10) published a paper whose 
findings concluded that general dentists and specialists 
in Ontario have an appropriate knowledge of BRONJ, 
but most are not comfortable performing oral surgery 
in patients taking BPs. Those who are comfortable rank 
higher in knowledge scores, suggesting greater educa-
tional efforts should be made to promote the knowledge 
of dentists regarding this complication.
This study aimed to evaluate whether changes in the 
teaching contents on medication-related osteonecrosis 
of the jaw led to changes in the knowledge of the surve-
yed students, quantifying whether the problem-solving 
capacity to carry out dental treatment on patients with 
MRONJ is significantly different according to the edu-
cational modifications introduced. Ethical approval was 




A cross-sectional descriptive study was carried out 
through a survey based on the proposal made by Alhus-
sain et al. (10). This survey was modified by dividing 
it into 4 parts: questions on MRONJ knowledge, ques-
tions on MRONJ knowledge acquisition, questions on 
standard practice, on complication and a final section on 
case studies on oral surgery, implant therapy, periodon-
tal treatment (scaling and root planning) and endodontic 
treatment. Each of the items on these sections had four 
possible answers. The student who was capable of co-
rrectly answering the clinical questions obtained a sco-
re of 12. The validation of accurate solutions was made 
by consensus between five experts, (three oral surgery 
specialists, one oral medicine specialist, and one bone 
and mineral metabolism specialist), taking as a clinical 
guide the proposal established by the AAOMS in 2009 
(11). The students were divided into two groups. The 
first group (Group A) was made up of students from the 
1st to the 5th dentistry courses that did the survey in No-
vember, 2015. The second group (Group B) was made 
up of those students (from the 1st to 5th) who carried 
out the same survey in November 2016. In turn, both 
groups were divided into two preclinical groups (1st and 
2nd year) and students of clinical course (3rd, 4th and 
5th year). The difference between Group A and Group 
B object of this study was the change in teaching con-
tents. The students in Group B received more training 
on the MRONJ than those in Group A. In particular, the 
contents of this area increased by four hours. One hour 
during the 2nd year on the subject of Pharmacology, two 
hours during the 4th year on the subject of Oral Surgery 
II and, finally, one hour in the 5th year on the subject of 
Integrated Dentistry.
All data were made anonymous and transferred to a da-
tabase, using the statistical software SPSS for Windows 
version 15.0. A descriptive analysis of variables was 
performed. All categorical variables are presented as 
percentages and continuous variables as mean and stan-
dard deviation. Student t test was used for comparison in 
case of quantitative variables, and chi-square or Fisher 
exact test in case of categorical variables. To compare 
more than two groups of quantitative values, ANOVA 
test and the Bonferroni’s post hoc procedure were used. 
Probability of less than 0.05 (p< 0.05) was accepted as 




A total of 175 surveys were collected (77.7%) from the 
total sample (n = 225 students: 125 Group A and 100 
Group B). The age range of the students in the sample 
was 18 to 28 years old and 66.1% of the respondents 
were women.
1. Knowledge acquisition.
The most widely used resource to be up-to-date on the 
subject was the Internet (85.2% Group A, 84.3% Group 
B), and secondly, specific courses on the subject (23.9% 
Group A, 36.1% Group B).
2. Degree of knowledge.
Less than 20% of students (19.6% of Group A, 19.3% 
of Group B) stated that they had no knowledge of BPs. 
Seventy-five percent of respondents reported that they 
received the first information on these drugs and their 
complications in the graduate program at University. 
The most well-known bisphosphonates were Alendro-
nate (Fosamax®: 56.9%, Group A, 67.5% Group B) 
and Zoledronic Acid (Zometa®: 56.9% Group A, 51.8% 
Group B) (Table 1).
Regarding BPs indications, 84.8% of the students in 
Group A and 81.9% of those in Group B indicated that 
they were used for the treatment of osteoporosis. A 
lower percentage, (38% Group A, 44.7% Group B), they 
were also used for the treatment of patients with bone 













Table 1: Knowledge percentage of about different bisphosphonates by the respon-
dents.
metastases (Table 2). 91.4% (Group A) and 94% (Group 
B) referred oral administration. The use of intravenous 
administration (IV) was recognized in 82% of respon-
dents. In Group A, 80% of the students did not know the 
treatment by stages of osteonecrosis, 73% of the respon-
dents of this group admitted to not knowing some type 
of treatment protocol. On the other hand, in Group B, the 
percentage of students who were unaware of treatment 
by stages was lower (50.6%), although 61.4% said they 
did not know any treatment protocols. A relatively low 
percentage of students (37.9% Group A, 43.4% Group 
B) recognized that other medicines other than BPs may 
cause osteonecrosis of the jaws. Denosumab was known 
for 20.5% and 39.8% of Group A and Group B, respec-
tively. On the other hand, 74.2% (Group A) and 60.2% 
(Group B) were unaware of the relation between Suniti-
nib and osteonecrosis of the jaws.
3. Common practice.
As expected, given the provenance of the study sample, 
more than 80% of the respondents had not treated any 
patient receiving BPs and more than 90% had not had a 
chance to see the treatment of patients with established 
osteonecrosis. 
Case resolution. (Table 3)
Tooth extraction
Right Answer: 45.8% (Group A) and 59.3% (Group B) 
of student would not carry out the treatment when the 
BP was administered by IV, while 38.3% (Group A) and 
KNOWLEDGE OF THE 
BISPHOSPHONATE INDICATIONS







MYELOMA 17,70% 28,90 %
Table 2: Knowledge of the bisphosphonate indications, reported by the two study 
groups.
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PROCEDURE BP and ORAL
< 3 YEARS
BP and ORAL
> 3  YEARS
BP and IV
TOOTH EXTRACTION To carry out treatment
(Group A: 38.3%)
(Group B: 37.8%)






IMPLANTS To carry out treatment
(Group A: 21.3%)
(Group B: 36.6%)







TREATMENT (root scaling 
and planning)
To carry out treatment
(Group A: 47.5%)
(Group B: 52.4%)
To carry out treatment
(Group A: 23.1%)
(Group B: 50%)





To carry out treatment
(Group A: 55%)
(Group B: 58.5%)
To carry out treatment
(Group A: 41.8%)
(Group B: 50%)
To carry out treatment
(Group A: 44.4%)
(Group B: 51.2%)
Table 3: Guideline of performance for dental procedures in patients to BP treatment and percentage of right answer in the respondents. O: oral 
Administration, IV: intravenous administration.
37.8% (Group B) would carry out the treatment when 
BP was orally administrated for less than three years. 
About 41% would stop BP 3 months before performing 
dental extraction when BP was taken orally for more 
than 3 years.
Implants
Right Answer: 46.3% (Group A) and 59.8% (Group B) 
of students would not carry out dental implants when 
the BP was administered by IV and only 21.3% (Group 
A) and 36,6% (Group B) would carry out treatment 
when BP was taken orally for less than three years. Be-
fore placing an implant, 26.6% of Group A respondents 
would stop oral treatment when BP was taken for more 
than three years. This same attitude would be applied by 
40.2% of the students in Group B.
Periodontal treatment (root scaling and planning). 
Right Answer: 33.3% of the students in Group A and 
39% of the students in Group B would perform a perio-
dontal treatment (root scaling and planning) when BP 
was administered by IV. 47.5% and 52.4% respectively, 
would carry out this same treatment when BP were taken 
orally for less than three years and only 23.1% and 50% 
(Groups A and B respectively) would do so when BPs 
were taken orally for more than three years.
Endodontic treatment.
Right Answer: 44.4% of Group A and 51.2% of Group 
B respondents would carry out an endodontic treatment, 
when BP was taken by IV. 55% and 58.5% (Groups A and 
B, respectively) would carry out endodontic treatment 
when BPs were given orally for less than three years. 
Only 41.8% (Group A) and 50% (Group B) would carry 
out endodontic treatment when BPs was taken orally for 
more than three years.
Considering that the maximum score to be obtained is 
12 points and the minimum score is 0, the average score 
obtained by the 92 students in Group A was 4.04 with a 
standard deviation (SD) of 3.46. In Group B, 83 students 
obtained an average score of 5.67 with a SD of 4.40. Sig-
nificantly, students in Group B had more right answers in 
the correct treatment related to the tooth extraction of the 
patients who received intravenously bisphosphonate (p= 
0.03), implant surgery in patients who had been taking 
oral bisphosphonates (p= 0.02) and the appropriate pe-
riodontal treatment of patients who had been taking oral 
bisphosphonates for more than three years (p= 0.001). 
The difference in the final score reached in the resolution 
of practical cases (4.04 in Group A versus 5.67 in Group 
B) was statistically significant (p = 0.001). 
Subdividing the study groups into two blocks (preclini-
cal and clinical) according to the course of study at the 
time of the survey allowed us to observe that the avera-
ge score of first and second year students in Group AP 
(preclinical) was 1.39. On the other hand, the average 
score of the third, fourth and fifth year students reached 
a value of 5.02. (Table 4).
For the students in Group BP (preclinical) in the first 
and second year the average score reached was 2.08, 
significantly lower than the score obtained by the stu-
dents in the last years of training (8,42) (Table 4). We 
did not observe differences between scores achieved by 
students of Group A compared to those of Group B in 
the first years of study, but there were differences among 
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Table 4: Inferential analysis between Groups A and B according to academic course. p: preclinical. c: clinical.
the students of last years. Significantly those in Group B 
achieved a higher score.
Among respondents in two study groups (A and B) there 
were no significant differences between variables, age, 
sex, Internet preference for knowledge acquisition, or 
importance of scientific journals as a source of knowled-
ge. However, denosumab (Prolia®) was significantly 
better known in Group B students in regard to those of 
Group A (p = 0.01). 
Discussion
To the best of our knowledge, López-Jorner et al. (12) 
published the first work in 2010 with similar characte-
ristics to our study. They compared knowledge about 
BRONJs among students and dentists in Murcia. As in 
our work, they observed that the Internet was the main 
source of knowledge for both groups, and that alendro-
nate was the best known bisphosphonate. In their results, 
the knowledge of dentists about BRONJs was higher 
than the student´s knowledge. In their opinion, it would 
be necessary to increase training on BRONJ in pre and 
postgraduate training.
In 2015, de Lima et al. (13) published the second work 
of similar characteristics carried out between dentistry 
students and dentists in Pernambuco (Brasil). Alarmin-
gly, they observed that 84.6% of dentists and 86% of 
dental students did not know the commercial names of 
bisphosphonates with the importance that this lack of 
knowledge has to make a correct medical history. 65.4% 
of dentists (most of them generalists) and 54% of stu-
dents did not know the indications of bisphosphonates. 
Dentists who had completed their studies more recently 
(less than five years of the survey) had better knowledge 
about BRONJ than dentists with more work experience.
In general, all of the literature reviewed agrees on the 
need to increase MRONJ training among dentists and 
this was the main objective of the present study. For this 
purpose, the survey model documented in Canada by Al-
hussain et al. (10) was modified, gathering information 
on the capacity for practical case resolution including 
different areas of dental treatment. This information 
allowed us to obtain quantitative assessments on the in-
fluence of changing teaching contents on bisphosphona-
tes, antiresorptive and osteonecrosis in dental students. 
In our view, the first step in improving MRONJ training 
should begin during undergraduate studies. Appropriate 
training in the management of these patients at the end 
of dentistry studies should be one of the main objectives 
to achieve an improvement in the reduction of MRONJ 
cases. The introduced teaching variable is easily repro-
ducible in any educational center. This variable only 
consisted in the increase of teaching hours on MRONJ. 
The present study emphasizes that we must improve our 
teaching efforts, since it shows that more than half of 
students do not know any action protocol to follow for 
patients receiving these medicines. Regarding knowled-
ge of a guide to the treatment of MRONJ, the American 
Society of Oral and Maxillofacial Surgery (AAOMS) (9, 
11) was the best known, but only by 15.7% of respon-
dents. Another data obtained from the study to be taken 
into account was that a low percentage of respondents 
(37.9% Group A, 43.4% Group B) recognized that other 
drugs (denosumab) can cause osteonecrosis of the jaws. 
However, denosumab was significantly better known 
among Group B students compared to Group A. 
In practical case resolution, significant differences were 
observed in favor of Group B in the activities related to 
surgery, (tooth extraction, implants) and to a lesser extent 
in some cases of periodontal treatment. This makes us think 
about the need to implement training on the management of 
these patients in periodontal and endodontic treatments.
In conclusion, our study highlights the need to impro-
ve teacher training of dental students on MRONJ in our 
context. This study also demonstrates that small teacher 
modifications are accompanied by significant improve-
ments in the clinical management of this complication.
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